JPRN-UMIN000030142已完成未知
A Phase Ib study of osimertinib with ramucirumab in EGFR mutated lung adenocarcinoma patients. (LY3009806-IIT-01) - Phase Ib study of osimertinib with ramucirumab (LY3009806-IIT-01)
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Any history of interstitial pneumonia, or any evidence of interstitial lung disease by CT scan. 2) Not able to swallow tablets. 3) Considered to be high risk of bleeding. 4) The patient has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism during the 3 months prior to first dose of protocol therapy 5) With serious illness or medical condition6) Undergone prior therapy, or procedure within defined period prior to enrollment 7) With local infection that requires procedure, or active systemic infection 8) HBS antigen (+) 9) Leptomeningeal carcinomatosis 10) Concurrent malignancy 11) Pregnant (must be negative serum pregnancy test or repeated urine test within 7 days prior to first dose), breast feeding, childbearing potential at enrollment, or not willing to use adequate contraceptive methods 12) Serious psychiatric condition that is hard to register this study 13) Known history of serious allergy 14) Other reason that the investigator would make the patient ineligible for entry into this study.
研究者
相似试验
已完成
1 期
A phase I study of osimertinib with bevacizumab and randomized phase II study of osimertinib with or without bevacizumab in EGFR mutated, T790M positive patients who had progressed EGFR-TKIs. (WJOG8715L)ung CancerJPRN-UMIN000023761West Japan Oncology Group87
已完成
2 期
Randomized phase II study of osimertinib plus ramucirumab and osimertinib for chemotherapy-naive patients with nonsquamous non-small cell lung cancer harboring EGFR mutationsEGFR mutation-positive non-squamous non-small-cell lung cancerAdvanced non-squamous non-small cell lung cancer, EGFR mutation positiveJPRN-jRCT2080224085Kanagawa Cancer Center120
进行中（未招募）
2 期
A Phase 2 Study of Osimertinib in combination with Platinum-pemetrexed in patients with EGFR-mutated Advanced non-small cell Lung cancer.on-squamous non-small cell lung cancerJPRN-jRCTs031180226Kobayashi Kunihiko66
已完成
不适用
A phase II study of osimertinib in patients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancerPatients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancerJPRN-UMIN000027655Division of Thoracic Oncology, Shizuoka cancer center18
招募中
不适用
Phase II study of osimertinib in patients with non-small cell lung cancer who acquired resistance to afatinibon-small cell lung cancerJPRN-UMIN000028166Asahikawa Medical University Hospital50